A comparison of the combination therapy consisting of microwave ablation (MWA) after bland lipiodol-based transarterial embolization (TAE) with MWA alone in the treatment of hepatocellular carcinoma (HCC) within the Milan criteria. Forty-nine patients in the TAE-MWA group (12 women and 37 men; mean age: 63.3 ± 9.6 years) with 55 tumors and 63 patients in the MWA group (18 women and 45 men; mean age: 65.9 ± 10.5 years) with 67 tumors were retrospectively enrolled in this study. For the investigation of treatment protocols based upon both safety and efficacy, patients’ cases were analyzed with regard to complications, local tumor progression (LTP), intrahepatic distant recurrence (IDR), overall survival (OS), and progression-free survival (PFS). There were no cases of major complications in either group. The LTP rate was 5.5% in the MWA-TAE group and 7.5% in the MWA group (p= 0.73). The rate of IDR was 42.9% in the MWA-TAE group and 52.4% in the MWA group (p= 0.42). The 12-, 24-, and 36-month OS rates starting at the date of tumor diagnosis were 97.7%, 85.1%, and 78.8% in the TAE-MWA group, and 91.9%, 71.4%, and 59.8% in the MWA group, respectively (p= 0.004). The 6-, 12-, and 24-month PFS rates were 76.5%, 55%, and 44.6% in the TAE-MWA group, and 74.6%, 49.2%, and 29.6% in the MWA group, respectively (p= 0.18). The combination therapy of TAE-MWA was significantly superior to MWA monotherapy according to OS in treating HCC within the Milan criteria.
一项关于米兰标准内肝细胞癌（HCC）治疗的对比研究：比较了单纯碘油经动脉栓塞术（TAE）联合微波消融（MWA）的序贯疗法与单独MWA治疗的疗效。本研究回顾性纳入了49例TAE-MWA组患者（女性12例，男性37例；平均年龄63.3±9.6岁）共55个肿瘤，以及63例MWA组患者（女性18例，男性45例；平均年龄65.9±10.5岁）共67个肿瘤。基于安全性和有效性的治疗原则，对患者的并发症、局部肿瘤进展（LTP）、肝内远处复发（IDR）、总生存期（OS）和无进展生存期（PFS）进行了分析。两组均未发生严重并发症。TAE-MWA组的LTP率为5.5%，MWA组为7.5%（p=0.73）。TAE-MWA组的IDR率为42.9%，MWA组为52.4%（p=0.42）。从肿瘤确诊日期起算，TAE-MWA组的12、24、36个月OS率分别为97.7%、85.1%、78.8%，而MWA组分别为91.9%、71.4%、59.8%（p=0.004）。TAE-MWA组的6、12、24个月PFS率分别为76.5%、55%、44.6%，MWA组分别为74.6%、49.2%、29.6%（p=0.18）。根据OS分析，TAE-MWA联合疗法在治疗符合米兰标准的HCC方面显著优于单纯MWA治疗。
肿瘤(癌症)患者之家